Fibrocell Science Inc (FCSC)
(Delayed Data from NSDQ)
$2.24 USD
+0.02 (0.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.24 USD
+0.02 (0.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.24 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Reata Successfully Completes Neuromuscular Disorder Study
by Zacks Equity Research
Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.
Savara Plunges on Failure of Late-Stage Study on Molgradex
by Zacks Equity Research
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
Fibrocell Up on FDA Designation for Gene Therapy Candidate
by Zacks Equity Research
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (FCSC) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Limbach, Health Insurance, Fibrocell, Camden and First Business
Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1
by Zacks Equity Research
Fibrocell (FCSC) misses estimates for earnings and sales in the first quarter of 2019.
Small Business Optimism Hits 4-Month High in April: 5 Picks
by Nalak Das
Small corporates create significant amount of jobs in the U.S. economy.
Is Fibrocell Science (FCSC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (FCSC) Outperforming Other Medical Stocks This Year?
Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
by Zacks Equity Research
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
by Zacks Equity Research
Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
by Zacks Equity Research
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates
by Zacks Equity Research
AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.
Fibrocell Science (FCSC) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Fibrocell Science (FCSC) closed the most recent trading day at $2.30, making no change from the previous trading session.
Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.
Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (FCSC) Outperforming Other Medical Stocks This Year?